{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T22:13:59Z","timestamp":1765923239856,"version":"3.48.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To explore a novel combination of methylation markers for the differential diagnosis of malignant ascites (MA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A cohort of 164 cancer patients and 20 patients with benign disease presenting with ascites was enrolled. Ascites was tested by means of cytopathological routine diagnosis and DNA methylation detection of SHOX2, RASSF1A, SEPTIN9 and HOXA9 in the cytological specimens. DNA methylation in bisulfite-converted DNA was determined using semi-quantitative methylation-specific real-time PCR (MS-PCR). In addition, Kaplan-Meier method was used to plot the Overall survival (OS) curve based on the methylation status of four genes to explore the relationship between gene methylation status and prognosis of patients with ascites. The Cox regression model was used to analyze the survival factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Methy-All-In-One Kit (OncoMe), a novel combination of SHOX2, RASSF1A, SEPTIN9 and HOXA9 methylation, led to an additional 29.9% increase in the detection rate of MA combined with the cytopathological test, resulting in a sensitivity of 76.2%. OncoMe showed high positive detection rates in Breast Cancer (87.5%), Pancreatic Cancer (83.3%), Gastric Cancer (79.5%), Cholangiocarcinoma (72.7%) and Ovarian Cancer (68.3%). Patients in the SHOX2 and SEPTIN9 methylation-positive groups had a significantly higher risk of disease progression than those in the negative groups. The OS of SHOX2 and SEPTIN9 gene methylation test negative group was higher than that of positive group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>OncoMe has potential for use as a biomarker for the detection of MA. Cytological examination combined with methylation detection can greatly improve the diagnosis rate of malignant ascites. The methylation status of SHOX2 and SEPTIN9 genes is significantly correlated with the prognosis of patients with ascites.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fgene.2025.1680036","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T22:10:18Z","timestamp":1765923018000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic and prognostic value of polygene methylation detection in ascites"],"prefix":"10.3389","volume":"16","author":[{"given":"Yang","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nrc3130","article-title":"A decade of exploring the cancer epigenome - biological and translational implications","volume":"11","author":"Baylin","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1183\/16000617.0063-2016","article-title":"Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment","volume":"25","author":"Bibby","year":"2016","journal-title":"Eur. Respir. Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3458420","DOI":"10.1155\/2022\/3458420","article-title":"Correlation between RASSF1A methylation in cell-free DNA and the prognosis of cancer patients: a systematic review and meta-analysis","volume":"2022","author":"Chen","year":"2022","journal-title":"J. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"825","DOI":"10.3892\/ijo.2011.1264","article-title":"Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates","volume":"40","author":"Dietrich","year":"2012","journal-title":"Int. J. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e84225","DOI":"10.1371\/journal.pone.0084225","article-title":"Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant and malignant pleural effusions","volume":"8","author":"Dietrich","year":"2013","journal-title":"Plos One"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/clinchem\/hvad084","article-title":"Circulating cell-free SEPT9 DNA methylation in blood is a biomarker for minimal residual disease detection in head and neck squamous cell carcinoma patients","volume":"69","author":"Dietrich","year":"2023","journal-title":"Clin. Chem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.3390\/cancers14071766","article-title":"Prognostic impact of circulating methylated homeobox A9 DNA in patients undergoing treatment for recurrent ovarian cancer","volume":"14","author":"Faaborg","year":"2022","journal-title":"Cancers."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.3390\/diagnostics13132131","article-title":"Cell-free methylated PTGER4 and SHOX2 plasma DNA as a biomarker for therapy monitoring and prognosis in advanced stage NSCLC patients","volume":"13","author":"Fleischhacker","year":"2023","journal-title":"Diagnostics"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1158\/1078-0432.CCR-16-1371","article-title":"Early detection of lung cancer using DNA promoter hypermethylation in plasma and sputum","volume":"23","author":"Hulbert","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nrg3230","article-title":"Functions of DNA methylation: islands, start sites, gene bodies and beyond","volume":"13","author":"Jones","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13148-016-0192-7","article-title":"Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites","volume":"8","author":"Jung","year":"2016","journal-title":"Clin. Epigenetics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/978-1-4939-7481-8_32","article-title":"DNA methylation analysis of free-circulating DNA in body fluids","volume":"1708","author":"Jung","year":"2018","journal-title":"Methods Molecular Biology Clift. NJ"},{"key":"B14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s12957-020-02097-y","article-title":"Quality assessment of the guidelines for the management of malignant pleural effusions and ascites","volume":"18","author":"Li","year":"2020","journal-title":"World J. Surg. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s00432-020-03188-9","article-title":"Signaling pathways and clinical application of RASSF1A and SHOX2 in lung cancer","volume":"146","author":"Li","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"967079","DOI":"10.3389\/fonc.2022.967079","article-title":"A detection panel of novel methylated DNA markers for malignant pleural effusion","volume":"12","author":"Liang","year":"2022","journal-title":"Front. Oncol."},{"key":"B7","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1665-2681(19)30865-8","article-title":"Evaluation of tumor markers for the differential diagnosis of benign and malignant ascites","volume":"13","author":"Liu","year":"2014","journal-title":"Ann. Hepatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1006\/gyno.1994.1333","article-title":"Ovarian cancer: screening, treatment, and follow-up","volume":"55","year":"1994","journal-title":"Gynecol. Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int. J. Gynecol. and Obstetrics"},{"key":"B30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.30699\/IJP.2021.130458.2450","article-title":"Diagnostic utility of combined CEA, CA15-3 and CA125 biomarkers and cytomorphology in suspicious and malignant serosal fluid","volume":"33","author":"Rahemi","year":"2021","journal-title":"Iran. J. Pathol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/bs.pmbts.2023.02.003","article-title":"Early epigenetic markers for precision medicine","volume":"198","author":"Raj","year":"2023","journal-title":"Prog. Molecular Biology Translational Science"},{"key":"B20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.anndiagpath.2017.01.007","article-title":"Methylation analysis of SHOX2 and RASSF1A in bronchoalveolar lavage fluid for early lung cancer diagnosis","volume":"27","author":"Ren","year":"2017","journal-title":"Ann. Diagnostic Pathology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13148-016-0267-5","article-title":"SEPT9 and SHOX2 DNA methylation status and its utility in the diagnosis of colonic adenomas and colorectal adenocarcinomas","volume":"8","author":"Semaan","year":"2016","journal-title":"Clin. Epigenetics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cell.2013.03.008","article-title":"Interplay between the cancer genome and epigenome","volume":"153","author":"Shen","year":"2013","journal-title":"Cell"},{"key":"B23","doi-asserted-by":"publisher","first-page":"565780","DOI":"10.3389\/fonc.2020.565780","article-title":"Performance evaluation of SHOX2 and RASSF1A methylation for the aid in diagnosis of lung cancer based on the analysis of FFPE specimen","volume":"10","author":"Shi","year":"2020","journal-title":"Front. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1126\/science.1230184","article-title":"Epigenetic reprogramming in cancer","volume":"339","author":"Suva","year":"2013","journal-title":"Science."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science."},{"key":"B26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2478\/jtim-2021-0046","article-title":"Lung adenocarcinoma-specific three-integrin signature contributes to poor outcomes by metastasis and immune escape pathways","volume":"9","author":"Wang","year":"2021","journal-title":"J. Transl. Intern. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.4238\/2015.May.4.11","article-title":"Cumulative methylation alternations of gene promoters and protein markers for diagnosis of epithelial ovarian cancer","volume":"14","author":"Xing","year":"2015","journal-title":"Genet. Mol. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00520-023-08299-w","article-title":"Advances in the treatment of malignant ascites in China","volume":"32","author":"Zhang","year":"2024","journal-title":"Support. Care Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.7150\/jca.21368","article-title":"DNA methylation analysis of the SHOX2 and RASSF1A panel in bronchoalveolar lavage fluid for lung cancer diagnosis","volume":"8","author":"Zhang","year":"2017","journal-title":"J. Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"5888844","DOI":"10.1155\/2023\/5888844","article-title":"DNA methylation analysis of the SHOX2 and RASSF1A panel using cell-free DNA in the diagnosis of malignant pleural effusion","volume":"2023","author":"Zhang","year":"2023","journal-title":"J. Oncol."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2025.1680036\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T22:10:19Z","timestamp":1765923019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2025.1680036\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":31,"alternative-id":["10.3389\/fgene.2025.1680036"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2025.1680036","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"article-number":"1680036"}}